• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Q/C Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    12/9/25 9:25:02 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $QCLS alert in real time by email
    false 0001321834 0001321834 2025-12-08 2025-12-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    Current Report

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 8, 2025

     

    Q/C Technologies, Inc.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   001-36268   22-2983783
    (State or other jurisdiction
    of incorporation)
      (Commission
    File No.)
      (IRS Employer
    Identification No.)

     

    1185 Avenue of the Americas, Suite 249    
    New York, NY   10036
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (856) 848-8698

     

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities Registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.001 per share   QCLS   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement

     

    On December 8, 2025, Q/C Technologies, Inc. (the “Company”) entered into a consulting agreement (the “Consulting Agreement”) with Ocean Avenue Holdings LLC (the “Consultant”), an entity affiliated with Martin Shkreli, pursuant to which, the Consultant agreed to provide certain consulting services to the Company, including evaluating companies and making related introductions, analyzing technologies and operations, reviewing and advising on potential acquisitions, introducing the Company to key opinion leaders and other industry experts, introducing prospective members of the Board of Directors of the Company and any other consulting or advisory services which the Company reasonably requests that the Consultant provides to the Company. The Consulting Agreement has a term of twelve (12) months, unless earlier terminated pursuant to the terms of the Consulting Agreement or upon the mutual written consent of the Company and the Consultant in accordance with the terms of the Consulting Agreement.

     

    Pursuant to the Consulting Agreement, the Company agreed to (i) pay the Consultant a monthly fee equal to $12,500 per month (or, $150,000 annually) payable in arrears on a monthly basis, (ii) issue warrants to purchase up to an aggregate of 212,500 shares of common stock, par value $0.001 per share (“Common Stock”), of the Company at an exercise price equal to $5.097 per share (the “Consultant Warrants”). The Consultant Warrants vest and become exercisable in four (4) substantially equal installments on each quarterly anniversary of the issuance date, provided that the Consultant continues to provide services to the Company through such applicable vesting dates and expire five (5) years from the date of issuance, and (iii) grant to the Consultant 212,500 restricted shares of Common Stock, which vest in four substantially equal installments on the quarterly anniversaries of the issuance date, provided that the Consultant continues to provide services to the Company through such vesting date and subject to the related restricted stock award agreement.

     

    Under the terms of the Consultant Warrants, the Consultant may not exercise the Consultant Warrants to the extent (but only to the extent) the Consultant or any of its affiliates would beneficially own a number of shares of Common Stock which would exceed 4.99%, or, at the election of the Consultant, 9.99% of the outstanding shares of Common Stock of the Company.

     

    The Consultant Warrants and shares of Common Stock issuable upon exercise of such Consultant Warrants were issued pursuant to an exemption from registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act of the Securities Act and in reliance on similar exemptions under applicable state laws.

     

    The foregoing descriptions of the Consulting Agreement and the Consultant Warrants do not purport to be complete and are qualified in their entirety by reference to the full texts of the Consulting Agreement and Form of Consultant Warrant, copies of which are filed as Exhibits 10.1 and 4.1 to this Current Report on Form 8-K, respectively, and incorporated herein by reference.

     

     

     

     

    Item 3.02. Unregistered Sales of Equity Securities.

     

    The matters described in Item 1.01 of this Current Report on Form 8-K are incorporated herein by reference. In connection with the issuance of the Consultant Warrants as described in Item 1.01 on this Current Report on Form 8-K, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act for transactions not involving a public offering.

     

    Item 8.01 Other Events.

     

    On December 9, 2025, the Company issued a press release announcing the Consulting Agreement. A copy of the press release is attached as Exhibit 99.1 hereto.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit Number   Description
    4.1   Form of Consultant Warrant.
    10.1   Consulting Services Agreement, dated as of December 8, 2025, by and between the Company and Ocean Avenue Holdings LLC.
    99.1   Press release, dated December 9, 2025.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      Q/C TECHNOLOGIES, INC.
         
    Date: December 9, 2025 By: /s/ Joshua Silverman
      Name: Joshua Silverman
      Title: Executive Chairman

     

     

     

    Get the next $QCLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QCLS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $QCLS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Q/C Technologies Launches Optical Processing Unit (OPU) Initiative to Develop Proprietary Silicon Photonic Computing Architecture for AI Inference

      New initiative aimed at developing optical computing technologies to overcome the performance and energy limitations of traditional electronic architectures New York, NY, March 18, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or "the Company"), today announced the launch of a new initiative to design and prototype a proprietary optical processing unit (OPU) aimed at tackling the growing performance and energy constraints in artificial intelligence inference infrastructure. Optical computing overcomes challenges posed by electronic GPUs. Artificial intelligence is dominated by one operation: the matrix multiplication. Photons can be configured to perform matrix m

    3/18/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors

    New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C Technologies" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Chelsea Voss to its Board of Directors. Ms. Voss is a computer scientist and Member of Technical Staff at OpenAI, where she has played a key role in the development, evaluation, and launch of some of the most advanced, widely used artificial intelligence systems. Her expertise spans machine learning infrastructure, model evaluation, hardware reliability, and published research contributions including results across image generation, ML interpretability, and reinforcement le

    1/20/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Quantum-Class Computing Developer Q/C Technologies Welcomes Strategic Advisor Martin Shkreli

    New York, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced that Martin Shkreli become a Strategic Advisor to the Company, contributing his experience in technology, industry contacts, financial innovation and early-stage growth. Q/C Technologies welcomes Martin as part of its expanding advisory team alongside James Altucher, further strengthening the Company's depth of expertise across computing, AI, and blockchain technologies. "I'm convinced that the next leap in frontier computing is optical, not purely quantum. Q/C's ‘quantum class' technology approach bridges f

    12/9/25 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QCLS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by White Billy Joe

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:10 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Friscia Stephen

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:11 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 4 filed by Voss Chelsea Sierra

    4 - Q/C TECHNOLOGIES, INC. (0001321834) (Issuer)

    4/15/26 6:29:11 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QCLS
    SEC Filings

    View All

    SEC Form 10-K filed by Q/C Technologies Inc.

    10-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    4/15/26 5:20:18 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form NT 10-K filed by Q/C Technologies Inc.

    NT 10-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    3/31/26 4:30:23 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Q/C TECHNOLOGIES, INC. (0001321834) (Filer)

    3/13/26 4:30:38 PM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $QCLS
    Leadership Updates

    Live Leadership Updates

    View All

    Q/C Technologies Appoints AI Systems Leader Chelsea Voss to Board of Directors

    New York, NY, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C Technologies" or "the Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Chelsea Voss to its Board of Directors. Ms. Voss is a computer scientist and Member of Technical Staff at OpenAI, where she has played a key role in the development, evaluation, and launch of some of the most advanced, widely used artificial intelligence systems. Her expertise spans machine learning infrastructure, model evaluation, hardware reliability, and published research contributions including results across image generation, ML interpretability, and reinforcement le

    1/20/26 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Q/C Technologies Appoints Technion Professor Dr. Steven Frankel as Senior Quantum Advisor to Advance Photonic and Quantum-Class Computing Initiatives

    Dr. Frankel brings extensive knowledge and deep expertise that bridges advanced physics and quantum technologies New York, NY, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Q/C Technologies, Inc. (NASDAQ:QCLS) ("Q/C" or the "Company"), a pioneer of quantum-class computing at the speed of light, today announced the appointment of Steven Frankel, Ph.D. as Senior Quantum Advisor. Dr. Frankel will help guide the Company's ongoing efforts in quantum-class photonic computing to advance the development and commercialization of Q/C's innovative Laser Processing Unit (LPU). Developed by LightSolver, Q/C's LPU is the world's first light and laser-based computing system designed to solve complex optimization an

    10/16/25 9:15:00 AM ET
    $QCLS
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care